ALA does a CR at 10c and the sp still is 12.5 - 13.5c as the...

ALA does a CR at 10c and the sp still is 12.5 - 13.5c as the lead manager isn't Bell Potter. Shows there is plenty of money out there for a bio-tech that hasn't even got its IND for ALA 101 to get to a ph1. Again comparing CHM to ALA , CHM should be valued at least at AUD 1b and IMU about 5b. Only explanation, either huge manipulation or the market stays away from anything related directly to Hopper. If just looking at the trials and the data already produced how in the world can a company like ALA be worth AUD 100 having nothing achieved while CHM's 1101 is close to a successful rego trial, having a world's first direct attacking solid cancer CD17 CAR-T going soon to ph1 and having several NK-cell trials ongoing in the US.

What is the ASX doing?

GLTA